ClinicalTrials.gg
CompletedNCT03655756Updated Aug 8, 2022Results posted

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

An Early Phase 1 interventional study of IFx-Hu2.0 in Cutaneous Melanoma, Stage III and Cutaneous Melanoma, Stage IV, sponsored by TuHURA Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by TuHURA Biosciences, Inc. · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
1,523rd of 1,750
7 · median 37
Started
2018
with 96 others
Phase 1
648 of 2,050
55 open now
Registered
1,395th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 1,523rd largest by enrollment of the 1,750 interventional ones that give a count, is one of 97 that started in 2018, is one of 648 in phase 1, and was the 1,395th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

239 more — sign in →

All 244 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events.

Read the detailed description

Six male and/or female adult patients (greater than or equal to 18 years old), of any ethnicity and race, with unresectable stage III or stage IV cutaneous melanoma with accessible lesions, will be eligible for enrollment and treatment with IFx-Hu2.0.

To be eligible for this study, patients with unresectable metastatic disease must have failed, refused or been deemed not candidates for at least one form of systemic anti-PD-1-based immunotherapy as well as BRAF inhibition, if BRAF V600 mutated. Talimogene laherparepvec (IMLYGIC®) is indicated for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Therefore, patients with unresectable cutaneous, subcutaneous, and nodal melanoma lesions recurrent after initial surgery must have failed, refused or been deemed not candidates for talimogene laherparepvec to be eligible for this study.

Enrollees will receive IFx-Hu2.0 at a single time point. Depending on the number of accessible lesions, a patient could receive up to three doses across three lesions (one dose per lesion). Forty milliliters of peripheral blood will be collected from these patients prior to treatment administration and at the follow-up visit four weeks later. The target dose will be 100 μg of plasmid DNA per lesion injected at a final dose volume of 200 μL per lesion. To allow for the observation of any acute toxicity in the first subject enrolled and prevent any occurrence of excessive toxicities in subsequent subjects, the first subject enrolled will receive a single dose of IFx-Hu2.0. Subsequent subjects will be administered the product after at least seven days. Beyond the first subject, the maximum number of lesions to be injected at any given time point in the study phase proposed is three lesions. These samples will be used to perform complete blood counts (CBC) and clinical chemistry tests. A urine sample will be obtained for urinalysis for protein and blood at the same frequency. Blood samples will be drawn for immune response evaluation as well. At the end of the study period, a biopsy of the lesion injected and a non-injected lesion (if applicable) will be collected. If the patient has a response to therapy, the patient will have the option of continuing the study at three-week intervals so long as they have not progressed. Optional tumor biopsies and peripheral blood collections may be obtained on subsequent treatment cycles.

03

Conditions studied

  • Cutaneous Melanoma, Stage III
  • Cutaneous Melanoma, Stage IV

Browse trials for

Keywords

  • Unresectable
  • Melanoma
  • pDNA
  • Plasmid DNA
  • Gene Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed unresectable stage III or stage IV malignant melanoma, with accessible cutaneous lesions
  • Must have greater than 3 mm
  • At least one injectable lesion and one lesion for at study conclusion. Lymphocyte count ≥ 500,000 cells/mL
  • (ECOG) performance status ≤ 2
  • Willing and able to give written,
  • If male or female of must be willing to use a during the study and for six months afterward. A woman is considered to be of childbearing potential unless she has had a surgical procedure that would accomplish sterility such a bilateral tubal ligation, hysterectomy or has not had menses for the past 12 months.
  • greater than three months
  • To be eligible for this study, patients with unresectable disease must have failed, refused or been deemed not candidates for at least one form of systemic -based immunotherapy as well as BRAF inhibition, if BRAF V600 mutated.
  • Patients with unresectable cutaneous, subcutaneous, and nodal melanoma lesions recurrent after initial surgery must have failed, refused or been deemed not candidates for talimogene laherparepvec to be eligible for this study.
  • The entry laboratory criteria for subject eligibility must be less than or equal to grade 1 adverse event levels for the parameters tested as defined by v5.0.

Exclusion criteria

Exclusion Criteria:

  • Known greater than 1 cm at screening.
  • of fewer than three months
  • Prior systemic anti-cancer treatment within three weeks from start of treatment (Day 0)
  • Current treatment with systemic (greater than 10 mg of daily prednisone) doses or other immunosuppressants such as those needed for solid organ transplants. Medications needed to treat conditions such as reactive airway disease are not excluded.
  • Pregnant or lactating women
  • Presence of any uncontrolled and significant medical or psychiatric condition which would interfere with trial safety assessments
  • Treatment with any product within the three weeks preceding injection
  • Immunizations for encapsulated bacteria were not given for patients who have undergone a splenectomy.
  • Serious underlying medical or psychiatric conditions, active infections requiring the use of antimicrobial drugs, or active bleeding that would make the subject unsuitable or unable to participate in the study
  • Concurrent chemotherapy or biological therapy. Concurrent radiotherapy is allowed as long as it is not the same site as the injected lesion.
  • Uncontrolled , , or infection
  • History of organ allograft transplantation
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point

    Therapeutic Classification: * Noncellular, Therapeutic Cancer Vaccine \> Immunomodulator Route of Administration: * Intratumoral injection of cutaneous, subcutaneous or nodal lesions Mechanism of Action: * Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface. Physiological Effect: * This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions.

    Biological: IFx-Hu2.0

Interventions

  • BiologicalIFx-Hu2.0

    Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).

    Also known as: pAc/emm55

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs)

    Safety was reported using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Feasibility was defined as the ability to treat at least five of the six patients enrolled without drug-related dose-limiting toxicity (DLT).

    Time frame: 28 ± 7 Days

Secondary outcomes

  1. Antitumor Response Induced by IFx-Hu2.0 Per RECIST v1.1 for Target Lesions.

    Evaluation of response rate and assessment of the antitumor immune responses induced by IFx-Hu2.0 per RECIST v1.1 for target lesions. Complete Response (CR), Disappearance of all target lesions. Partial Response (PR), ≥ 30% decrease in the sum of the longest diameters of target lesions compared with baseline. Stable Disease (SD), Neither sufficient shrinkage to qualify for partial or complete response (CR or PR) nor sufficient increase to qualify for progressive disease (PD). Progressive Disease (PD), Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: 28 ± 7 days post treatment

07

Results

Posted Aug 8, 2022

Participant flow

This study had a goal of six evaluable patients. It was the intent of the study team to recruit an additional two patients to be screened and enrolled if any of the existing patients were lost to follow-up, withdrew consent, or exhibited disease progression.

Participant flow — Overall Study
MilestoneIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
Started7
Completed6
Not completed1
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs)

Safety was reported using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Feasibility was defined as the ability to treat at least five of the six patients enrolled without drug-related dose-limiting toxicity (DLT).

Time frame:
28 ± 7 Days
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs)
ParticipantsIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
Participants Analyzed6
Serious Adverse Events (SAEs)1
Dose Limiting Toxicity (DLT)0
SecondaryAntitumor Response Induced by IFx-Hu2.0 Per RECIST v1.1 for Target Lesions.

Evaluation of response rate and assessment of the antitumor immune responses induced by IFx-Hu2.0 per RECIST v1.1 for target lesions. Complete Response (CR), Disappearance of all target lesions. Partial Response (PR), ≥ 30% decrease in the sum of the longest diameters of target lesions compared with baseline. Stable Disease (SD), Neither sufficient shrinkage to qualify for partial or complete response (CR or PR) nor sufficient increase to qualify for progressive disease (PD). Progressive Disease (PD), Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
28 ± 7 days post treatment
Reported as:
Count of participants · Participants
Antitumor Response Induced by IFx-Hu2.0 Per RECIST v1.1 for Target Lesions.
ParticipantsIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
Complete Response (CR)0
Partial Response (PR)1
Stable Disease (SD)2
Progressive Disease (PD)3

Adverse events

Collected over Day 0 to 28 days ± 7 business days from the last dose administered.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point1/7 (14.3%)2/7 (28.6%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
Clostridial sepsisBlood and lymphatic system disorders1/7
Multiple organ dysfunction syndromeGeneral disorders1/7
PneumatosisGastrointestinal disorders1/7
Most frequent other events
Showing 10 of 17
Most frequent other events
EventIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
Injection site reactionGeneral disorders5/7
Tumor hemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/7
ConstipationGastrointestinal disorders2/7
InsomniaPsychiatric disorders2/7
Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/7
Back painMusculoskeletal and connective tissue disorders1/7
ErythemaGeneral disorders1/7
Lymphocyte count decreasedInvestigations1/7
PruritusSkin and subcutaneous tissue disorders1/7
HypertensionVascular disorders1/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
<=18 years0
Between 18 and 65 years1
>=65 years6
Sex: Female, Male
Sex: Female, Male(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
Female3
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
United States7
AJCC Clinical Staging
AJCC Clinical Staging(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion/Time Point
Stage III1
Stage III C4
Stage IV2
08

Study locations

1 site
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jul 2020, 20 months.

Results were first posted in Aug 2022, 2 years after primary completion.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 20 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Aug 31, 2018
StartActual
Nov 5, 2018
Primary completionActual
Jul 10, 2020
CompletionActual
Nov 30, 2020
Results first posted
Aug 8, 2022
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03655756
Lead sponsor
TuHURA Biosciences, Inc.
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Nov 5, 2018
Primary completion
Jul 10, 2020
Completion
Nov 30, 2020
Results posted
Aug 8, 2022
Last update
Aug 8, 2022

Study contacts

Joseph Markowitz, MD, PhD
principal investigator · Collaborator

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0

Start the discussion